newsfilter
← Latest News
GlobeNewswire·

Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide

TORONTO, April 18, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ